American Gene Technologies International Stock

americangene.comHealthcare / BioTech & PharmaFounded: 2007Funding to Date: $72.88MM

American Gene Technologies ("AGT") is an emerging gene and cell therapeutics company with a proprietary lentiviral platform capable of broad applications including large and orphan indications, infectious disease, immune-oncology, and monogenic disorders.

Register To Buy and Sell Shares

For more details on financing and valuation for American Gene Technologies International, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access American Gene Technologies International’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like American Gene Technologies International.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

David Pauza Ph.D
Chief Science Officer
Norman Rogers
Executive, Business Development
Jeffrey Galvin
Co-Founder, Chief Executive Officer & Board Member
Neil Lyons
Chief Financial Officer & Executive Vice President

Board Members

Julia Brown
Qi Tang
Jeffrey Galvin
Aaron Galvin
Tommy Thompson JD

Frequently Asked Questions About American Gene Technologies International’s Stock

Can you buy American Gene Technologies International’s stock?
American Gene Technologies International is not publicly traded on NYSE or NASDAQ in the U.S. To buy American Gene Technologies International’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell American Gene Technologies International’s stock?
Yes, you can sell stock of a private company like American Gene Technologies International. Forge can help you sell your American Gene Technologies International stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is American Gene Technologies International’s stock price?
American Gene Technologies International is a privately held company and therefore does not have a public stock price. However, you may access American Gene Technologies International’s private market stock price with Forge Data.
What is American Gene Technologies International’s stock ticker symbol?
American Gene Technologies International does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

AGT Spins Out Addimmune, Focusing on Functional HIV Cure
American Gene Technologies (AGT) is spinning out a new company, Addimmune, to focus on developing a cure for HIV. Addimmune will continue AGT's work on AGT103-T, a gene and cell therapy that completed Phase I trials with positive safety results. The therapy is a single-dose treatment that delivers gene-therapy modified, HIV-specific CD4 T cells to people with HIV, with the aim of restoring natural immune control of the virus.
American Gene Technologies spinout Addimmune to go public through SPAC merger
The article discusses grocery delivery start-up, Instacart's valuation reaching $39 billion following its latest funding round of $265 million. This valuation is triple its previous one in 2020, indicating a surge in demand for its service amid the pandemic. The firm plans to use the funds for expanding its business.
Rockville company working on HIV cure will go public
American Gene Technologies International plans to make its Addimmune division a publicly traded company via a special purpose acquisition company (SPAC). Addimmune is developing a gene and cell therapy for HIV, and the SPAC spinoff could raise $500 million to fund larger clinical studies. The public offering is expected to be completed in early 2024.
Updated on: May 21, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.